Home » SOSEI AND VECTURA ANNOUNCE COMPLETION OF NVA237 TRIAL
SOSEI AND VECTURA ANNOUNCE COMPLETION OF NVA237 TRIAL
Sosei and Vectura Group have announced that their collaborative product, NVA237, a novel inhaled once-daily treatment for chronic obstructive pulmonary disease (COPD), had successfully completed a Phase IIb multiple dose-ranging clinical trial.
NVA237 is being developed and commercialized by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol, under the terms of a global licence agreement signed in April 2005.
The outcome of the study supports the progression of NVA237 and Novartis are proceeding as planned with the development program.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May